SCM
CABA icon

Silverarc Capital Management’s Cabaletta Bio CABA Stock Holding History

Silverarc Capital Management’s Portfolio CABA Stock Details CABA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-42,022
Closed -$511K – 76
2021
Q3 		$511K Buy
+42,022
New +$388K 0.29% 67

Other funds holding CABA

Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
SC
Samlyn Capital New York $5.86B AUM 36.3% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Silverarc Capital Management's CABA Position: Q4 2021 in Review

Silverarc Capital Management sold out of Cabaletta Bio (CABA) in Q4 2021, closing a stake of 42,022 shares — an estimated $511K sold.

Silverarc Capital Management first reported a position in CABA in Q3 2021 and held it in 1 quarter. The position peaked at $511K in Q3 2021. 66 funds tracked by Wall St. Rank hold CABA as of Q4 2021.

  • Silverarc Capital Management reported no remaining Cabaletta Bio position as of Q4 2021 after selling out during the quarter.
  • Silverarc Capital Management sold 42,022 Cabaletta Bio shares in Q4 2021, an estimated $511K.
  • Silverarc Capital Management first reported a position in Cabaletta Bio in Q3 2021 and held it in 1 quarter.
  • Silverarc Capital Management's Cabaletta Bio position peaked at $511K in Q3 2021.
  • 66 funds tracked by Wall St. Rank held Cabaletta Bio as of Q4 2021.

Based on Silverarc Capital Management's 13F filing for Q4 2021, filed 14 Feb 2022.